Articles
<![CDATA[PRESEPSIN AND PROCALCITONIN VALUES TO DETERMINE THE PROGNOSIS OF UROSEPSIS ]]>
<![CDATA[Addin, Sofyan Rais]]>;
<![CDATA[Djojodimedjo, Tarmono]]>;
<![CDATA[Rizaldi, Fikri]]>
<![CDATA[ Indonesian Journal of Urology Vol 25 No 2 (2018) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v25i2.463
<![CDATA[Objective: To evaluate the prognostic value of presepsin and procalcitonin in patient with urosepsis. Material & Method: This is an observational prospective study. Patients who fulfilled the criteria for urosepsis at Soetomo Hospital Surabaya were enrolled. Presepsin and procalcitonin were measured at first admission. All patients were managed according to standard urosepsis therapy. At the 28th day of treatment, patients were evaluated and classified into survivor and non-survivor. The statistical analysis were tested with logistic regression test using software SPSS 23. Results: 30 urosepsis patients were included in this study with average age was 48.3 years (range 21-77 years). There were 23 survivor and 7 non-survivor. Mean presepsin values were higher in non-survivor than in survivor but the difference was not significant (4405 ± 4664 vs 4042 ± 2643, p=0.259). Mean procalcitonin value was significantly higher in non-survivor than in survivor (7.68 ± 6.81 vs 3.27 ± 2.74, p=0.013). Using the cut off value ≥2.24 ng/ml, procalcitonin can predict mortality in 28 days with sensitivity 71.4% and specificity 47.8%. Conclusion: Presepsin can not be used to determine the prognosis of urosepsis patients. Procalcitonin showed a significant correlation with outcome of urosepsis patients so it can be use to determine the prognosis of urosepsis.]]>
<![CDATA[THE EFFECT OF DEXAMETHASONE ON SPERMATOGONIUM AND SERTOLI CELL OF IPSILATERAL TESTIS IN UNILATERAL TESTICULAR TORSION WISTAR RAT ]]>
<![CDATA[Efendi, Ferdyan Rachmat]]>;
<![CDATA[Renaldo, Johan]]>;
<![CDATA[Djojodimedjo, Tarmono]]>
<![CDATA[ Indonesian Journal of Urology Vol 25 No 2 (2018) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v25i2.466
<![CDATA[Objective: To investigate the effect of dexamethasone on spermatogonium and sertoli cell of ipsilateral testis in unilateral testicular torsion strain wistar rat. Material & Method: Experimental study with post-test only control group design. The present study was conducted on 30 Wistar male rats aged 10 – 12 weeks grouped into 5 groups. Group I was the normal/sham operation group (KN), group II was left testicular torsion for 4 hours group and followed by manual detorsion (K1), group III was left testicular torsion for 10 hours group and followed by manual detorsion (K2), group IV was left testicular torsion for 4 hours group and given dexamethasone 10 mg/kg body weight subcutaneously 30 minutes before manual etorsion (D1), and group V was left testicular torsion for 10 hours group and given dexamethasone 10 mg/kg body weight subcutaneously 30 minutes before manual detorsion. All rats had left orchidectomy 4 hours after detorsion. The number of spermatogonium and sertoli cells were counted in histological seminiferous tubular testis that have obtained Haematoxylin Eosin staining. Data were analyzed by ANNOVA followed by Post Hoc Tukey for spermatogonium and Kruskal Wallis followed by Mann Whitney test for sertoli cell. Differences were considered significant at p <0.05. Results: There was significant difference in the mean number of spermatogonium between K1 & D1 group. Otherwise, there was no significant difference in the mean number of spermatogonium between K2 & D2. There was significant difference in the mean number of Sertoli cells between K1 & D1 group, likewise that between K2 & D2 group. Conclusion: These results suggest that dexamethasone has protective effect in spermatogonium and sertoli cell in testicular torsion for 4 hours.]]>
<![CDATA[THE EFFECTIVENESS OF TAMSULOSIN, SOLIFENACIN, AND COMBINATIONS THERAPY TAMSULOSIN ADDED SOLIFENACIN ON LOWER URINARY TRACT SYMPTOMS AFTER DOUBLE J STENT INSERTION ]]>
<![CDATA[Pramana, Ida Bagus Putra]]>;
<![CDATA[Rizaldi, Fikri]]>;
<![CDATA[Djojodimedjo, Tarmono]]>
<![CDATA[ Indonesian Journal of Urology Vol 26 No 2 (2019) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v26i2.503
<![CDATA[Objective: Insertion of DJ Stent is a procedure that is often done by urologist. Insertion of DJ Stent can cause LUTS complaints and greatly affect the physical and psychosocial health of patients. The aim of this study was to determine the effectiveness difference of tamsulosin therapy 0.4 mg/day, solifenacin 5 mg/day and the combination of tamsulosin therapy 0.4 mg/day added solifenacin 5 mg/day to manage LUTS complaint after DJ Stent insertion. Material & Methods: This study was a randomized placebo-controlled trial. There were 4 groups, group I received placebo, group II received tamsulosin 0.4 mg/day, group III received solifenacin 5 mg/day, and group IV received combination therapy of tamsulosin 0.4 mg/day added solifenacin 5 mg/day. Evaluation based on International Prostatic Symptom Score (IPSS) and Ureteral Stent Symptom Questioner (USSQ) score. Data were analyzed using SPSS 21.0. It is said to be significant if p<0.05. Results: There were a total of 32 samples consist of 19 (59.3%) men and 13 (40.6%) women. There were significant improvements in the score of total IPSS, IPSS storage and IPSS quality of life score in patients who received combination therapy (p<0.05) when compared with patients who received monotherapy. The highest decrease in USSQ scores 1, 2, 3, 4, 5 and 6 were in the group that received combination therapy when compared with the monotherapy group. Conclusion: The combination therapy is safe and effective to improve IPSS total, IPSS storage and IPSS Quality of Life scores compared with monotherapy.]]>
<![CDATA[PROFILE OF PATIENTS WITH URINARY TRACT STONE AT UROLOGY DEPARTMENT OF SOETOMO GENERAL HOSPITAL SURABAYA IN JANUARY 2016-DECEMBER 2016 ]]>
<![CDATA[Kurniawan, Reza]]>;
<![CDATA[Djojodimedjo, Tarmono]]>;
<![CDATA[Rahayu, Anny Setijo]]>
<![CDATA[ Indonesian Journal of Urology Vol 27 No 1 (2020) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v27i1.506
<![CDATA[Objective: To identify the profile of patients with urinary tract stones at the Urology Department of Soetomo General Hospital Surabaya in January 2016-December 2016. Material & methods: This was descriptive retrospective research conducted at the Urology Department of Soetomo General Hospital Surabaya. The data were obtained from medical records of patients diagnosed with urinary tract stone, with the amount of data collected was 62. The variables included were age, gender, address, main complaint, type and location of urinary tract stone. Results: The ratio of male:female among patients with urinary tract stone is 33:29. Most of the patients with urinary tract stone were aged 46-60 years old (52%), came with the main complaint of flank pain (79%), had the uric acid type of urinary tract stone (48%), and had urinary tract stone located at the kidneys (65%). Conclusion: Profile of patients with urinary tract stone at the Urology Department of Soetomo General Hospital Surabaya is as following: Ratio of male:female among patients with urinary tract stone is 33:29. Most of the patients with urinary tract stone were aged 46-60 years old, came with the main complaint of flank pain, had the uric acid type of urinary tract stone, and had urinary tract stone located at the kidneys.]]>
<![CDATA[EFFECT OF VITAMIN E (α-TOCOPHEROL) ADMINISTRATION ON SPERM MOTILITY AND MORPHOLOGY OF SPRAGUE DAWLEY STRAIN RATS AFTER CISPLATIN TREATMENT ]]>
<![CDATA[Aditya, Dimas Visa]]>;
<![CDATA[Djojodimedjo, Tarmono]]>;
<![CDATA[Soebadi, Doddy M]]>
<![CDATA[ Indonesian Journal of Urology Vol 26 No 1 (2019) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v26i1.539
<![CDATA[Objective: To evaluate the protective effects of vitamin E α-tocopherol isomer against the toxicity of cisplatin on sperm motility and morphology in Sprague Dawley rats. Material & Methods: Twenty-four rats were grouped into four groups (n=6). The control group (CN) was injected with normal saline, second group (CP) was injected with cisplatin, the third group (P1) was injected with cisplatin and vitamin E 50 mg/kgBW for 7 weeks P.O, the fourth group (P2) was injected with cisplatin and vitamin E 200 mg/kgBW for 7 weeks P.O. Vitamin E was given from 3 weeks before cisplatin injection and 4 weeks following cisplatin injection. At 7th week, all the samples were undergoing bilateral orchidectomy. Vitamin E that being used in this study was α-tocopherol isomer. Results: Cisplatin decreased motility and morphology of spermatozoa significantly against controls. Vitamin E 50 mg/kgBW and 200 mg/kgBW significantly increased motility of spermatozoa (p<0.05) compared to those in the cisplatin group only. Vitamin E 50 mg/kgBW, and 200 mg/kgBW did not have a significant difference in spermatozoa motility compare to control groups. Vitamin E 50 mg/kgBW and 200 mg/kgBW could increase the spermatozoa morphology significantly compare to those cisplatin only group. Vitamin E 50 mg/kgBW, and 200 mg/kgBW did not have a significant difference in spermatozoa morphology compared to control groups. Conclusion: α-tocopherol 50 mg/kgBW and 200 mg/kgBW provided a same protective effect against spermatozoa damage especially in motility and morphology aspect due to cisplatin exposure. Therefore, in this study it was more recommended to use α-tocopherol in 50 mg/kgBW dose than 200 mg/kgBW.]]>
<![CDATA[DIFFERENCES OF TESTOSTERONE LEVELS TO THE DURATION OF INHALED NICOTINE EXPOSURE IN SPRAGUE-DAWLEY MALE WHITE RATS ]]>
<![CDATA[Ramadhan, Ido Putra]]>;
<![CDATA[Djojodimedjo, Tarmono]]>;
<![CDATA[Soebadi, Doddy M]]>
<![CDATA[ Indonesian Journal of Urology Vol 27 No 1 (2020) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v27i1.593
<![CDATA[Objective: To analyze the differences in testosterone level in young Sprague-Dawley white rats after exposure of inhaled nicotine and the recovery effect that occurs when nicotine exposure is stopped. Material & Methods: This is an experimental study, which variable measurements were taken after the experimental animals were treated. The experimental grouping process was carried out randomly, with repetitions of 12 experimental animals in each group and the control group as a comparison (negative control). This study using male Sprague-Dawley white rats as samples. Nicotine administration was carried out by inhalation using pure nicotine (C10H14N2), which was diluted using distilled water. Treatment group 1 (P1) was given nicotine exposure for 30 days, treatment group 2 (P2) for 15 days, and treatment group 3 (P3) for 15 days and then stopped for 15 days compared to the control group. Testosterone levels are measured using the ELISA (Enzyme-Linked Immunosorbent Assay) method in the morning. Results: The lowest testosterone levels were found in the P1 and significantly different from the P2 (p=0.029) and P3 (p=0.001). The results of the analysis show that a decrease in testosterone levels in mice is related to the duration of nicotine exposure. Conclusion: Testosterone levels in the control group were significantly higher compared to the treatment group that exposed by nicotine inhalation with a dose of 4 mg/kgBW/day for 15 days, and also there is a significant recovery effect on testosterone levels after the treatment was halted for 15 days.]]>
<![CDATA[COMPARISON OF BLADDER CANCER CELLS APOPTOSIS INDUCED BY METFORMIN, CISPLATIN, AND COMBINATION OF METFORMIN-CISPLATIN: IN VITRO STUDY ]]>
<![CDATA[Lumbangaol, Arifai]]>;
<![CDATA[Hakim, Lukman]]>;
<![CDATA[Soebadi, Doddy M]]>;
<![CDATA[Djojodimedjo, Tarmono]]>
<![CDATA[ Indonesian Journal of Urology Vol 27 No 1 (2020) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v27i1.600
<![CDATA[Objective: To evaluate the effect of metformin, cisplatin, and their combination on apoptosis of bladder cancer cells. Material & Methods: Urothelial cell lines 5637 were cultured until 80% confluence. Cells were exposed to metformin and cisplatin at certain doses for 24 and 48 hours. Cytotoxicity test was carried out by calculating the viability of bladder cancer cells using the MTT assay until IC50 of each drug was obtained. IC50 Metformin and Cisplatin obtained from the cytotoxicity test were used to induce apoptosis in bladder cancer cells using TUNEL assay. Additional combination doses of Metformin and cisplatin used to induce apoptosis were ¼ IC50 (metformin + cisplatin), ½ IC50 (metformin + cisplatin), and IC50 (metformin + cisplatin). Results: IC50 of metformin was 15 uM while cisplatin was 18 uM with a 48-hour exposure. There was a difference in the mean value of the apoptosis index in all treatment groups compared to control except for the group exposed to IC50 metformin and ¼ IC50 (metformin + cisplatin). Conclusion: Metformin administration solely is not able to increase bladder cancer cell apoptosis. Conversely, the administration of Cisplatin can significantly increase bladder cancer cell apoptosis. The combination of Metformin and Cisplatin can significantly increase bladder cancer cell apoptosis. The rate of apoptosis in line with an increase dose of the combination of these two drugs.]]>
<![CDATA[COMPARISON OF PAIN PERCEPTION BETWEEN INTRAVENA TRAMADOL INJECTION WITH PERIPROSTATIC LIDOCAINE INJECTION IN TRANSRECTAL ULTRASONOGRAPHY GUIDED PROSTATE BIOPSY PATIENT ]]>
<![CDATA[Sawal, Zuhri]]>;
<![CDATA[Djatisoesanto, Wahjoe]]>;
<![CDATA[Djojodimedjo, Tarmono]]>
<![CDATA[ Indonesian Journal of Urology Vol 27 No 2 (2020) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v27i2.646
<![CDATA[Objective: To compare the pain perception between intravenous tramadol administration and PNB technique using lidocaine in TRUS guided prostate biopsy. Material & Methods: The design of this study is a prospective randomized clinical trial. The population of this study is BPH patients who will undergo TRUS guided prostate biopsy procedure according to the indication in our center. Randomization was done for the determination of groups 1 and 2. Group 1 was given tramadol injection 100 mg intravenously, while group 2 was given a local injection of lidocaine periprostatic. The Wong-Baker scale directly determined pain perception during the procedure. Results: The total samples in this study were 20 samples that met the inclusion and exclusion criteria with 10 samples in each group. The lidocaine group had a lower Wong Baker’s pain scale in both probe USG insertion and prostate biopsy than the tramadol group. However, it’s not statistically significant (p=0.089; p=0.125, respectively). Conclusion: The use of intravenous tramadol can be used as an alternative anesthetic/analgesic method in prostate biopsy patients. The pain scale of the intravenous tramadol can be compared with periprostatic lidocaine with lesser complications compared to periprostatic lidocaine.]]>
<![CDATA[COMPARISON OF PAIN PERCEPTION BETWEEN INTRAVENA TRAMADOL INJECTION WITH PERIPROSTATIC LIDOCAINE INJECTION IN TRANSRECTAL ULTRASONOGRAPHY GUIDED PROSTATE BIOPSY PATIENT ]]>
<![CDATA[Sawal, Zuhri]]>;
<![CDATA[Djatisoesanto, Wahjoe]]>;
<![CDATA[Djojodimedjo, Tarmono]]>
<![CDATA[ Indonesian Journal of Urology Vol 27 No 2 (2020) ]]>
Publisher : <![CDATA[Indonesian Urological Association ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32421/juri.v27i2.646
<![CDATA[Objective: To compare the pain perception between intravenous tramadol administration and PNB technique using lidocaine in TRUS guided prostate biopsy. Material & Methods: The design of this study is a prospective randomized clinical trial. The population of this study is BPH patients who will undergo TRUS guided prostate biopsy procedure according to the indication in our center. Randomization was done for the determination of groups 1 and 2. Group 1 was given tramadol injection 100 mg intravenously, while group 2 was given a local injection of lidocaine periprostatic. The Wong-Baker scale directly determined pain perception during the procedure. Results: The total samples in this study were 20 samples that met the inclusion and exclusion criteria with 10 samples in each group. The lidocaine group had a lower Wong Baker’s pain scale in both probe USG insertion and prostate biopsy than the tramadol group. However, it’s not statistically significant (p=0.089; p=0.125, respectively). Conclusion: The use of intravenous tramadol can be used as an alternative anesthetic/analgesic method in prostate biopsy patients. The pain scale of the intravenous tramadol can be compared with periprostatic lidocaine with lesser complications compared to periprostatic lidocaine.]]>
<![CDATA[Risk Factors of Urethro-cutaneous Fistula Development in Hypospadias Surgery ]]>
<![CDATA[Permana, Wien]]>;
<![CDATA[Tarmono, Tarmono]]>;
<![CDATA[Renaldo, Johan]]>
<![CDATA[ Jurnal Kedokteran Brawijaya Vol 31, No 3 (2021) ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Brawijaya ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.21776/ub.jkb.2021.031.03.9
<![CDATA[Urethrocutaneous fistula development is the most common complication found hypospadias surgery. Several factors associated with the incidence of fistulas are the age at the time the surgery. The type of hypospadias, the degree of chordae, the operative technique applied and catheter type. This study aimed to determine the risk factors associated with the urethro-cutaneous fistula development in hypospadias surgery. The results showed that from 310 hypospadias patients undergoing urethroplasty, urethra cutaneous fistula development occurred among 105 patients (30.6%) with a mean age of surgery 10.89+6.27 years. Hypospadias type has a significant difference with the incidence of urethro-cutaneous fistula development (p = 0.027). Age (p = 0.615), degree of chordae (P=0.805), operative technique (P=0.901) and catheter type (P=691) do not have a significant impact to urethro-cutaneous fistula development. It can be concluded that operative urethroplasty has a risk of urethra-cutaneous fistula that associated with hypospadias type.]]>
